Skip to main content
Article

Small-molecule-induced liquid-liquid phase separation suppresses the carcinogenesis of β-catenin

Jin YanDepartment of Hepatology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, P. R. ChinaHeyuan LiuDepartment of Hepatology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, P. R. ChinaWenguang YangDepartment of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, P. R. ChinaNa LiuDepartment of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, P. R. ChinaJingmei WangInstitute for Stem Cell & Regenerative Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, ChinaZhanfeng LiDepartment of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, P. R. ChinaTianya LiuDepartment of Hepatology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, P. R. ChinaSiqi YanDepartment of Hepatology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, P. R. ChinaWangxiao HeDepartment of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, P. R. China. [email protected]
2025en
ABI

Abstract

Biomolecular condensates are droplet-like membrane-less compartments in cells that can sequester proteins. Modulating these condensates offers a promising way to durably inhibit disease-driving proteins that lack enzymatic activity and thus elude traditional drug targeting. However, many such proteins remain beyond the reach of current condensate-modulating strategies. Here we show an alternative approach: by destabilizing target proteins, we directly induce their liquid-liquid phase separation (LLPS), causing them to form condensates. Using this strategy, we develop a small molecule RQ that forces β-catenin (an oncogenic protein in liver cancer) into cytoplasmic condensates. This sequestration prevents β-catenin from entering the nucleus and activating cancer-promoting genes. In nanoparticle form (albumin-bound Abroquinone), RQ is selectively taken up by β-catenin-driven liver cancer cells and kills them while sparing normal cells. This approach suppresses β-catenin-driven tumor growth and overcomes immune evasion, demonstrating a promising paradigm for targeting previously untargetable proteins by inducing their phase separation.

Identifiers

Citations and references

Cited by 20 references